BioCentury | Mar 22, 2021
Finance

Tracking the rise in venture funding for gene, cell therapy companies: Data Byte

...nanoparticles for siRNA delivery; Gyroscope Therapeutics Ltd., which is developing AAV-based gene therapies for the eye; and Adaptimmune Therapeutics plc...
...Therapeutics Inc. Tmunity Therapeutics Inc. Legend Biotech Corp. Neogene Therapeutics Inc. Allogene Therapeutics Inc. Celularity Inc. BioNTech SE BlueRock Therapeutics L.P. Genevant Sciences Corp. Adaptimmune Therapeutics plc Alexandria...
BioCentury | Mar 17, 2021
Product Development

Immatics’ early data may add to growing optimism for cell therapies in solid tumors

...in patients with mesothelin-expressing solid tumors. In January, Adaptimmune Therapeutics plc...
BioCentury | Mar 6, 2021
Product Development

The pace of new modality approvals is picking up

...reach the market could be TCR-based cell therapies. Adaptimmune Therapeutics plc...
...its ADAP NY-ESO TCR from originator Adaptimmune, and Adaptimmune...
...a given target. GSK’s targets NY-ESO-1 and Adaptimmune’s...
BioCentury | Jan 22, 2021
Emerging Company Profile

SciNeuro reunites GSK R&D vets to bring CNS therapies to China

...Stead, who held BD roles at GSK, Nimbus Therapeutics LLC, Inovio Pharmaceuticals Inc. (NASDAQ:INO) and Adaptimmune Therapeutics plc...
BioCentury | Jun 3, 2020
Finance

June 2 Financial Quick Takes: follow-ons for Allogene, Adaptimmune, plus DCVC Bio, Windtree and BMS

...on safety and efficacy (see “Allogene’s Allogeneic CAR T Data” ). Adaptimmune raises $225.5M follow-on Adaptimmune Therapeutics plc...
...class. Targets S1PR1 (S1P1; EDG1) - Sphingosin 1-phosphate receptor 1 BioCentury Staff Windtree Therapeutics Inc. Allogene Therapeutics Inc. DCVC Bio Adaptimmune Therapeutics plc KL4...
BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

...treat addiction, appointed James Noble as chairman. Noble, who co-founded and served as CEO of Adaptimmune Therapeutics plc...
BioCentury | Mar 5, 2020
Management Tracks

Mott retires from NEA

...posted annual revenues exceeding $1.5 billion and had over 3,000 employees. Mott is chairman of Adaptimmune Therapeutics plc...
BioCentury | Feb 22, 2020
Management Tracks

Everest names new CEO; plus Merck, Gilead, Turning Point, Adaptimmune, AskBio and more

...opportunities. VP and Controller Kevin Moran will serve as acting CFO. T cell therapy company Adaptimmune Therapeutics plc...
...hereditary disorders. BioCentury Staff Gilead Sciences Inc. Asklepios BioPharmaceutical Inc. H3 Biomedicine Inc. OptiNose Inc. Laboratory for Advanced Medicine Inc. Everest Medicines Ltd. Adaptimmune Therapeutics plc...
BioCentury | Jan 24, 2020
Financial News

January fund-raising sets pace with $2.6B in follow-ons

...9% discount to ImmunoGen's Wednesday close of $4.68; the company added $0.23 to $4.91 Thursday. Adaptimmune Therapeutics plc...
...the company’s close of $4.14 on Tuesday, when it proposed the offering after market hours. Adaptimmune...
...showing four partial responses to its SPEAR T cell therapies in various solid tumors (see “Adaptimmune...
BioCentury | Jan 24, 2020
Financial News

2020 hits ground running with $2.5B in January follow-ons

...9% discount to ImmunoGen's Wednesday close of $4.68; the company added $0.23 to $4.91 Thursday. Adaptimmune Therapeutics plc...
...the company’s close of $4.14 on Tuesday, when it proposed the offering after market hours. Adaptimmune...
...showing four partial responses to its SPEAR T cell therapies in various solid tumors (see “Adaptimmune...
Items per page:
1 - 10 of 130
BioCentury | Mar 22, 2021
Finance

Tracking the rise in venture funding for gene, cell therapy companies: Data Byte

...nanoparticles for siRNA delivery; Gyroscope Therapeutics Ltd., which is developing AAV-based gene therapies for the eye; and Adaptimmune Therapeutics plc...
...Therapeutics Inc. Tmunity Therapeutics Inc. Legend Biotech Corp. Neogene Therapeutics Inc. Allogene Therapeutics Inc. Celularity Inc. BioNTech SE BlueRock Therapeutics L.P. Genevant Sciences Corp. Adaptimmune Therapeutics plc Alexandria...
BioCentury | Mar 17, 2021
Product Development

Immatics’ early data may add to growing optimism for cell therapies in solid tumors

...in patients with mesothelin-expressing solid tumors. In January, Adaptimmune Therapeutics plc...
BioCentury | Mar 6, 2021
Product Development

The pace of new modality approvals is picking up

...reach the market could be TCR-based cell therapies. Adaptimmune Therapeutics plc...
...its ADAP NY-ESO TCR from originator Adaptimmune, and Adaptimmune...
...a given target. GSK’s targets NY-ESO-1 and Adaptimmune’s...
BioCentury | Jan 22, 2021
Emerging Company Profile

SciNeuro reunites GSK R&D vets to bring CNS therapies to China

...Stead, who held BD roles at GSK, Nimbus Therapeutics LLC, Inovio Pharmaceuticals Inc. (NASDAQ:INO) and Adaptimmune Therapeutics plc...
BioCentury | Jun 3, 2020
Finance

June 2 Financial Quick Takes: follow-ons for Allogene, Adaptimmune, plus DCVC Bio, Windtree and BMS

...on safety and efficacy (see “Allogene’s Allogeneic CAR T Data” ). Adaptimmune raises $225.5M follow-on Adaptimmune Therapeutics plc...
...class. Targets S1PR1 (S1P1; EDG1) - Sphingosin 1-phosphate receptor 1 BioCentury Staff Windtree Therapeutics Inc. Allogene Therapeutics Inc. DCVC Bio Adaptimmune Therapeutics plc KL4...
BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

...treat addiction, appointed James Noble as chairman. Noble, who co-founded and served as CEO of Adaptimmune Therapeutics plc...
BioCentury | Mar 5, 2020
Management Tracks

Mott retires from NEA

...posted annual revenues exceeding $1.5 billion and had over 3,000 employees. Mott is chairman of Adaptimmune Therapeutics plc...
BioCentury | Feb 22, 2020
Management Tracks

Everest names new CEO; plus Merck, Gilead, Turning Point, Adaptimmune, AskBio and more

...opportunities. VP and Controller Kevin Moran will serve as acting CFO. T cell therapy company Adaptimmune Therapeutics plc...
...hereditary disorders. BioCentury Staff Gilead Sciences Inc. Asklepios BioPharmaceutical Inc. H3 Biomedicine Inc. OptiNose Inc. Laboratory for Advanced Medicine Inc. Everest Medicines Ltd. Adaptimmune Therapeutics plc...
BioCentury | Jan 24, 2020
Financial News

January fund-raising sets pace with $2.6B in follow-ons

...9% discount to ImmunoGen's Wednesday close of $4.68; the company added $0.23 to $4.91 Thursday. Adaptimmune Therapeutics plc...
...the company’s close of $4.14 on Tuesday, when it proposed the offering after market hours. Adaptimmune...
...showing four partial responses to its SPEAR T cell therapies in various solid tumors (see “Adaptimmune...
BioCentury | Jan 24, 2020
Financial News

2020 hits ground running with $2.5B in January follow-ons

...9% discount to ImmunoGen's Wednesday close of $4.68; the company added $0.23 to $4.91 Thursday. Adaptimmune Therapeutics plc...
...the company’s close of $4.14 on Tuesday, when it proposed the offering after market hours. Adaptimmune...
...showing four partial responses to its SPEAR T cell therapies in various solid tumors (see “Adaptimmune...
Items per page:
1 - 10 of 130